What ESC 2021 guidelines say about use of Mineralocorticoid Receptor Antagonist (MRA) in HFrEF? - Video
|
Overview
The European Society of Cardiology (ESC) has recently issued guidelines to include Mineralocorticoid Receptor Antagonist (MRA) besides ACE-I and beta-blockers, in all patients with HFrEF to reduce mortality and the risk of HF hospitalization (class 1A recommendation). The aim of this ESC Guideline is to help health professionals manage people with heart failure (HF) according to the best available evidence.
In this video, Dr. Prem Aggarwal a senior cardiologist, New Delhi gives an insight into the new guidelines and recommendations by ESC while also discussing the treatment modalities for patients with HF.
For more details, check out the below mentioned link:
Speakers
Dr Prem Aggarwal, (MD Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder and Chairman of Medical Dialogues. He focuses on news and perspectives about cardiology, and medicine related developments at Medical Dialogues. He can be reached out at drprem@medicaldialogues.in